Allocating Care, Capacity, & Capital Beyond the Hospital
Home-based care is changing more than where treatment occurs. Health systems are under pressure to manage sustained cost growth, constrained clinical capacity, workforce limitations, and rising demand without relying indefinitely on additional facility-based capacity. These pressures make site of care a strategic question: which patients truly require hospital or ambulatory infrastructure, and where could care be delivered differently without compromising quality?
Home-based care can create meaningful value. In a randomized U.S. hospital-at-home trial, adjusted acute-care costs were 38% lower than conventional hospitalization, while 30-day readmissions were 7% compared with 23% for patients treated in the hospital. Other research has shown that appropriately selected patients can receive hospital-level care at home with comparable clinical outcomes and a better patient experience. Hospital-at-home (HaH) provides acute, hospital-level care to eligible patients at home; home infusion delivers treatments such as intravenous medications with appropriate pharmacy and clinical support; and remote monitoring uses connected technology to support ongoing clinical management. Each model serves a different purpose and requires a distinct investment case.
That potential makes hospital at home and other home-based care a healthcare strategy decision, not simply a new delivery channel. It changes how health systems deploy clinical capacity, workforce, technology, logistics, and capital across the delivery network, while introducing different delivery costs, reimbursement arrangements, and financial returns. The Site-of-Care Allocation Playbook provides a structured way to determine which patients and phases of care should move, what infrastructure must move with them, and how the rest of the system should adapt. The objective is not to maximize care delivered at home, but to place each phase of care in the setting that can support it most effectively and create the strongest clinical, capacity, and economic value.
Allocate Patient Pathways, Not Entire Service Lines
The first gate is clinical and patient suitability.
Site-of-care decisions should be made at the patient-pathway level, based on clinical needs, treatment phase, expected trajectory, required support, and informed preference. Neither diagnosis nor a target for moving more care home should determine the setting.
Evidence supports carefully selected alternatives to conventional hospitalization. A 2025 randomized trial involving 1,150 acutely ill patients across three hospitals compared hybrid hospital-at-home (HaH) with conventional inpatient care. Death or unplanned readmission within 30 days occurred in roughly 17% of the home group and 20% of the hospital group, meeting the study’s noninferiority criterion. Patient comfort was also higher at home. The findings support a hospital at home program as an option for eligible patients, not as the default setting for acute care.
The right comparison depends on the type of care being delivered. Hospital-at-home should be compared with inpatient care. Home infusion may need to be compared with a hospital outpatient department, physician office, or ambulatory infusion center. Remote patient monitoring may support ongoing care rather than replace an in-person visit.
Those alternatives can produce very different economics. A 2026 matched-cohort analysis of more than 52,000 home infusion and outpatient cases found outpatient costs were 42% higher for infusions delivered in hospital outpatient departments than for infusions delivered across alternative sites, without significant differences in several near-term utilization and adverse-event measures. But the alternative sites included homes, ambulatory infusion centers, and physician offices, and excluded cases in which hospital outpatient treatment was considered medically necessary. Leaders should compare all clinically appropriate settings rather than assume home offers the strongest economics.
Investment cases should define the patient population and treatment phase precisely. A pathway may begin in hospital, move home after stabilization, use an ambulatory setting for a specific intervention, and rely on monitoring between encounters.
Leadership defines the operating boundaries; clinicians determine individual suitability within them. Better economics cannot justify the wrong care setting.
Key Takeaway
Allocate the patient and treatment phase, not the diagnosis. Home should compete against the best clinically appropriate alternative.
Explore Our Healthcare & Life Sciences Consulting Services
P&C Global’s healthcare and life sciences practice partners with leading health systems and innovators.
Build Hospital-at-Home Infrastructure Around the Patient
The second gate is operational readiness.
Moving to a hospital at home model does not remove the infrastructure required to deliver it. It redistributes that infrastructure across home health care providers, logistics, technology, and households. Before a pathway expands, health systems should define the operating envelope within which care can be delivered reliably.
Design the Care Model End to End
The care process must work from admission through treatment, monitoring, and escalation. Medications need reliable preparation and delivery. Diagnostics need clear turnaround times and ownership of results. If a patient’s condition worsens, the escalation path must be clear from identification through transport and hospital acceptance.
Workforce requirements also change. Field clinicians face travel time, geography, safety considerations, and scheduling complexity. Remote teams need enough capacity to review incoming information and act on it, while specialist, after-hours, and surge coverage must remain available.
Geography shapes what a home-based model can support. A 2025 randomized trial tested hospital-level care at home across three rural U.S. and Canadian regions, where distance, patient density, and access to services can affect delivery. Patients receiving care at home were more active and reported better experiences than those treated in the hospital, while costs did not differ significantly. However, patients moved home relatively late in their acute-care episode, limiting the time during which the home model could affect costs and potentially reducing the opportunity to demonstrate savings.
Patient density, travel time, service radius, transition timing, and census all affect operating efficiency. Staffing, service-area, and capacity assumptions should therefore reflect local conditions rather than another market’s model.
Design Monitoring for Reliable Clinical Response
Technology creates value only when the care model can turn data into timely clinical action. Health systems need to define who reviews incoming data, which signals require intervention, how quickly teams must respond, and when a patient should move to another level of care. Monitoring should scale only when clinical response capacity can scale with it.
A 2026 study of continuous vital-sign monitoring at home shows why alert design matters. Among 98 patients monitored after hospital discharge, the system generated a median of 74 alerts per patient per day without filtering. Severity- and duration-based filters reduced that to 5 alerts per patient per day, an 84% reduction.
Monitoring design should therefore proceed in two steps. First, health systems should tune alert thresholds to reduce unnecessary notifications without missing clinically important events. Second, they should size staffing, escalation pathways, and response times around the volume and urgency of alerts that remain. More data creates little value if teams cannot reliably identify and act on the signals that require intervention.
Technology design must also account for system failure. Device malfunction, incomplete readings, or platform outages require clear backup procedures and ownership. A pathway is not operationally ready if it depends on uninterrupted technology.
Treat the Home as Part of the Care Infrastructure
The home must also support the care being delivered. Power, connectivity, medication storage, accessibility, transport, language support, and caregiver availability can all affect whether a pathway operates safely and reliably.
Some conditions are non-negotiable clinical requirements. Others are barriers the organization can address. If otherwise eligible patients lack connectivity, transportation, language support, an appropriate home setup, or caregiver assistance, health systems should determine whether those barriers can be addressed before excluding them from home-based care. Without funded support, these requirements can systematically limit access for disadvantaged patients or shift labor, utility costs, coordination responsibilities, and clinical risk to families.
The operating model should therefore specify which supports the health system will provide, how caregiver capacity and consent will be assessed, and when home-based care is inappropriate because required support cannot be provided safely. Leaders should also monitor enrollment and exclusion patterns to determine whether eligibility criteria or household requirements are creating unequal access.
Home conditions and patient preference can materially narrow the population a program can serve. A study of HaH consultations at an urban academic medical center found that only 22.5% ultimately enrolled. Among the most common reasons patients declined were a preference to remain in the hospital and home conditions that were unsuitable for acute care.
Clinical eligibility therefore does not guarantee patient acceptance. Health systems need to articulate the patient value proposition, which may include greater comfort, convenience, mobility, proximity to family, and less disruption from a hospital stay. Any differences in patient cost should also be made transparent rather than assumed to favor home care. Programs should explain what care at home will require from the patient and household, what support the health system will provide, and preserve a meaningful choice of setting when clinically appropriate.
As programs expand, health systems should also identify which capabilities can be shared across pathways and which must remain dedicated. Hospital-at-home, home infusion, and remote monitoring may share pharmacy logistics, mobile clinical teams, diagnostics, command-center operations, data integration, and escalation networks.
Each shared capability needs a clear owner, defined capacity, and service standards so growth in one pathway does not weaken another.
Key Takeaway
Define the operating envelope before scaling the pathway. Growth should follow demonstrated capacity across workforce, logistics, diagnostics, technology, household support, and escalation.
Explore Our Healthcare IT Transformation Services
P&C Global’s healthcare IT transformation services embed cyber resilience in connected care delivery.
Build the Full Economic Case
The third gate is economics and funding.
Lowering the cost of an individual patient’s care does not automatically create savings for the health system. The investment case must separate patient-level savings from costs the health system can actually remove, capture costs across the full pathway, test shared-infrastructure economics, and align funding with who captures the benefit.
Separate Patient-Level Cost from Avoidable System Cost
A hospital at home model can reduce the resources required for an individual patient’s course of care. The randomized HaH trial cited earlier demonstrates that potential, with materially lower acute-care costs alongside lower 30-day readmissions.
Those findings demonstrate potential savings at the patient level, but a lower-cost home stay does not automatically reduce total health system expense. Staffing, facilities, and other fixed costs may remain even after care moves home.
For example, if home-based care costs $3,000 less to deliver but only $1,000 of hospital expense can actually be removed, the health system captures only part of the apparent savings.
The executive test is: Which costs actually disappear, over what period, and through what operating change?
Map the Timing of Cost Removal
Costs leave the system on different timelines. Some variable expenses may fall as soon as care moves home. Staffing may change only after volume reaches a sufficient threshold. Fixed capacity may remain until units are consolidated, staffing models change, or planned expansion can be reduced.
Finance should model when costs actually leave the system rather than convert average inpatient cost into assumed savings. The business case should distinguish immediately avoidable costs from those that depend on scale or a broader operating decision.
Set the Right Economic Boundary
The analysis should also capture costs beyond the initial stay when they are material to the pathway. A UK randomized trial involving 1,055 older adults found approximately £3,017 lower combined health, social-care, and informal-care costs at six months for its hospital-at-home model. Hospital transfer or readmission was higher at one month, while the difference was no longer evident at six months.
The cost boundary should match the pathway. Depending on the model, the analysis may need to include subsequent utilization, social care, household support, or other resources beyond the initial phase of treatment. Without that broader view, savings in one part of the system can obscure costs created elsewhere.
Test the Economics of Shared Infrastructure
Individual pathways should not be evaluated as though every capability were dedicated to a single program. A new pathway may be able to draw on capabilities already built for another model, reducing the incremental infrastructure required to support it.
Duke’s HaH program illustrates the model. Patients were monitored remotely, while Duke Home Infusion nurses visited two to three times a day to draw labs and administer medications. Rather than build every capability from scratch for HaH, the program leveraged existing home-infusion resources, supported by hospitalists and remote monitoring.
Infrastructure can also support adjacent pathways as they develop. Virtua Health expanded use of the remote monitoring technology, physician and nursing resources, and 24/7 command center originally built for its hospital-at-home program to support a post-discharge care model. The example shows how an established home-care platform can support additional patient populations without creating an entirely separate operating structure.
That does not mean shared infrastructure automatically improves economics. Health systems should identify which capabilities can genuinely be reused, how much capacity remains, and the incremental resources another pathway requires. A pathway may become viable when it uses existing clinical, technology, or logistics capacity; another may require enough dedicated staffing and infrastructure that it must justify those costs on its own.
Align Funding With Who Captures the Value
The organization funding the pathway may not be the organization receiving the economic benefit.
A payer may capture lower claims expense while the provider funds additional clinical, technology, or logistics infrastructure. A health system may improve access or operating performance without receiving payment that reflects the value created. Patients and families may also absorb time, travel, or caregiving costs that do not appear in the provider business case.
Funding arrangements should reflect who makes the investment and who captures the value. In the U.S., that calculation differs materially across home-based models. Under CMS’s Acute Hospital Care at Home initiative, participating hospitals must obtain an individual waiver for each hospital seeking to provide inpatient-level care at home. The initiative is currently authorized through September 30, 2030. That policy horizon should inform contract terms, investment timing, and how much infrastructure should be built as fixed capacity versus designed to scale or be redeployed if reimbursement rules change.
Home infusion operates under a different Medicare payment structure. Medicare Part B provides a home infusion therapy benefit for professional services associated with certain drugs, including nursing, patient education, and monitoring, while the drug, pump, and related supplies may be paid separately through the durable medical equipment benefit. A health system moving infusion from a hospital outpatient department to the home may therefore reduce total cost without capturing all of that economic benefit itself. Contracting with payers or other partners may be necessary when the savings accrue elsewhere in the system.
Remote monitoring creates a different alignment challenge. Medicare pays separately for defined components of remote patient monitoring, including device-related and clinical-management services. Those payments compensate activity, but they do not necessarily reward the provider for downstream benefits such as avoided admissions or lower total cost of care. Under arrangements such as the Medicare Shared Savings Program, however, organizations that reduce total spending while meeting quality requirements may participate in the resulting savings. That can create a stronger economic connection between investment in monitoring and the broader value it generates.
Not every program needs to produce immediate savings. Access, quality, resilience, or strategic capacity may justify investment, but the objective and funding source should be explicit. Leaders should understand which revenues are available under the applicable reimbursement model, who captures any avoided cost or capacity benefit, and whether the economics remain viable if payment policy or contract terms change.
Key Takeaway
Separate patient-level savings from avoidable system cost, test shared-infrastructure economics, and align funding with who captures the value before deciding whether a home-based pathway is economically sustainable.
Make Released Capacity Produce Value
The fourth gate is network value and governance.
Hospital at home care may release hospital beds, infusion chairs, clinical time, or other constrained resources. Released capacity creates value only when it relieves a constraint, supports additional activity, reduces cost, or changes a capital decision.
A study that transitioned selected immune globulin patients from clinic to home illustrates the point. Moving 27 patients reduced monthly clinic visits and created just over 100 hours of additional infusion-chair availability each month.
Those hours represent available capacity, not realized value. The organization could use them to treat additional patients, reduce waiting time, change staffing, accommodate other therapies, or avoid adding future infusion capacity. Each choice produces a different economic result.
Apply the same test to hospital capacity. Leaders should identify the constraint being relieved and the action that converts availability into value. Does it reduce emergency department boarding? Improve transfer acceptance? Support additional procedures? Address seasonal demand? Defer expansion?
A capacity-realization plan should identify the intended use, accountable owner, baseline, and value measure before the benefit enters the investment case.
Do not count the same capacity twice. Capacity cannot simultaneously be eliminated to capture its full fixed-cost saving and retained to support incremental admissions. If beds remain operational, the business case should capture value from their productive use rather than assume the underlying cost disappeared.
Capital planning requires a higher evidence threshold. Deferring a major hospital capital project may preserve flexibility because leadership can restart it if conditions change. Redesigning or canceling a project can be harder to reverse, while capital already committed to completed infrastructure is harder still to recover.
The less reversible the decision, the stronger the evidence should be.
Before distributed care changes a major facility plan, executives should require evidence that substitution remains durable across demand cycles, patient populations, reimbursement conditions, and operating disruptions.
The business case should also specify what sustained performance would actually change: project timing, bed count, facility configuration, investment scope, or another defined commitment. It should establish the conditions that would cause leadership to revisit that decision.
Key Takeaway
Count released capacity only when it supports a defined operating or capital decision, and require stronger evidence as the resulting commitment becomes harder to reverse.
Apply the Site-of-Care Allocation Playbook
Together, these four gates form the Site-of-Care Allocation Playbook.
The framework determines whether a pathway should Proceed, Scale, Redesign, or Stop.
Decision Gate | Executive Test | Required Output |
Clinical & Patient Suitability | Is this patient and treatment phase appropriate for another setting? | Eligible population, exclusions, reassessment requirements, patient choice |
Operational Readiness | Can we deliver the pathway reliably? | Operating envelope, service area, capacity limits, contingencies |
Economics & Funding | Can the model be funded sustainably? | Economic case, funding model, downside scenario, investment rationale |
Network Value & Governance | What system value will it create, and who is accountable for realizing it? | Capacity-realization plan, accountable leaders, thresholds, investment stages |
The gates provide a sequence of executive tests, but the analysis is iterative rather than linear. Clinical eligibility establishes the potential patient population and achievable census; census and geography then shape staffing, logistics, and unit economics; reimbursement affects which operating models are viable; and operational constraints may require leaders to revisit eligibility criteria, service areas, or pathway design.
Findings from later gates should therefore feed back into earlier decisions. Clinical and safety requirements remain non-negotiable, but the operating model should be refined as leaders test different scenarios and learn where the pathway can be delivered reliably and economically. A pathway should advance only when the resulting design satisfies all four gates.
Consider a health system evaluating a hospital-to-home pathway after initial stabilization.
- The Clinical & Patient Suitability Gate defines which patients qualify, what conditions must be met, and when reassessment is required.
- The Operational Readiness Gate finds that nursing and pharmacy services can support the proposed region, but diagnostic turnaround and transfer arrangements meet required standards only within a smaller area. The provider must therefore either narrow the rollout to the geography the current operating model can support or expand diagnostic and transfer capacity to meet expected demand.
- The Economics & Funding Gate finds that avoidable hospital costs alone will not fully fund the new model. However, existing mobile clinical teams and technology reduce the incremental investment enough for the pathway to produce a positive net economic benefit. If those shared capabilities were not available, leadership would need to redesign the model, identify another funding source, or stop the project.
- The Network Value & Governance Gate identifies a recurring inpatient-capacity constraint that the pathway could help relieve. The decision is Redesign rather than region-wide expansion.
Leadership narrows the model to the geography the operating model can reliably support. Once the revised pathway meets all four gates, it can Proceed. Operations owns the plan for using released hospital capacity, while finance validates whether the expected benefits are realized.
After launch, reliable delivery, sufficient patient volume, acceptable outcomes, sustainable economics, and demonstrated capacity value could support Scale. Persistent gaps would require further Redesign. Failure to meet core clinical or safety requirements would require Stop.
The Playbook shifts the executive question from:
Should we move more care home?
to:
Under what conditions should this pathway play a larger role in the delivery network?
Key Takeaway
Use the four gates to decide whether a pathway should proceed, scale, be redesigned, or stop.
Govern the Pathway After Approval
Approval should specify who has authority to change, pause, or stop a pathway when performance falls below agreed thresholds or operating conditions change. Patient mix, staffing, partner performance, reimbursement, technology, and demand may all shift after launch, requiring the original decision to be revisited. Governance should define which changes require management action.
Set Review Triggers at Approval
Review triggers should be established before launch.
Clinical triggers may include adverse-event patterns, repeated inappropriate escalations, or changes in the population being served. Operating triggers may include missed visits, diagnostic delays, staffing shortages, partner failures, or repeated technology outages. Economic triggers may include lower-than-expected volume, rising delivery cost, reimbursement changes, or benefits that fail to materialize.
A trigger should identify when the assumptions behind the original approval no longer hold.
Define the Management Response
Each material trigger should have predefined responses. Depending on the issue, leadership may narrow the service area, change eligibility criteria, add support, replace a partner, revise funding, pause expansion, or retire the pathway. Clinical leaders should also retain authority to suspend intake immediately when safety requirements cannot be met.
Escalation should be interpreted carefully. A clinically appropriate transfer may show that the safety process worked as intended. Performance measures should distinguish appropriate escalation from avoidable failure rather than reward low transfer rates alone.
Make Exceptions Expire
Temporary workarounds can become permanent if no event forces reconsideration. Every material exception should therefore have a named owner, documented rationale, review date, and renewal requirement.
For example, a health system launching a HaH pathway might temporarily restrict enrollment in part of its service area while additional diagnostic or transfer capacity is being established. The exception would expire once the required capability is in place or at a specified review date, whichever comes first.
At review, leadership should either allow the exception to expire or explicitly renew it and determine whether the underlying operating model needs to change.
Key Takeaway
Keep the original decision current with predefined review triggers, clear intervention authority, and time-bound exceptions.
Building a Better Delivery Network in Healthcare
Hospital at home is one part of the delivery network, not the strategy itself. The goal of home based care is to place each phase of care in the setting that best fits the patient’s needs. Some care will move home, some will remain in hospitals or ambulatory settings, and many pathways will span more than one setting.
The Site-of-Care Allocation Playbook helps leaders make those choices without treating greater home-care volume as the objective. It connects clinical suitability, operational readiness, economics, and network value in one decision process.
The measure of progress is not how much care leaves the hospital. It is whether each phase of care is delivered in the setting that creates the strongest clinical, capacity, and economic value, supported by a health system that can deliver it reliably.
